Wed.Apr 17, 2024

article thumbnail

Roche touts near-complete suppression of multiple sclerosis relapse for injectable Ocrevus

Fierce Pharma

One-year data continued to support a more convenient, injectable version of Roche’s blockbuster multiple sclerosis (MS) drug Ocrevus ahead of an FDA decision, the Swiss pharma said. | One-year data continued to support a more convenient, injectable version of Roche’s blockbuster multiple sclerosis drug Ocrevus ahead of an FDA decision, the Swiss pharma said.

FDA 334
article thumbnail

What Does the FTC’s $7M Fine Against Cerebral Mean for the Industry?

MedCity News

This week, the FTC ordered Cerebral to pay a $7 million fine, accusing the company of mishandling users’ sensitive health data and misleading consumers about cancellation policies. Experts agree that other virtual healthcare providers need to work on their legal and compliance strategies in order to avoid a similar fate. The post What Does the FTC’s $7M Fine Against Cerebral Mean for the Industry?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Eli Lilly's tirzepatide scores again, this time in 2 sleep apnea trials

Fierce Pharma

In addition to their acclaimed efficacy against diabetes and obesity, GLP-1 drugs are gaining traction for their potential to treat a variety of other common disorders. | In addition to their acclaimed efficacy against diabetes and obesity, GLP-1 drugs are gaining traction for their potential to treat a variety of other common disorders. Now, two trials have shown that Eli Lilly’s weight loss product Zepbound (tirzepatide) can help patients overcome obstructive sleep apnea (OSA).

Patients 299
article thumbnail

Eli Lilly Shows Obesity Drug Zepbound Can Treat Sleep Apnea Too

MedCity News

Eli Lilly drug tirzepatide, marketed as Zepbound for weight management, has results from two Phase 3 studies showing reductions in the breathing problems caused by obstructive sleep apnea. Lilly is now preparing regulatory submissions to add this indication to the drug’s label. The post Eli Lilly Shows Obesity Drug Zepbound Can Treat Sleep Apnea Too appeared first on MedCity News.

article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Medincell, AbbVie link up in long-acting injectable development pact worth up to $1.9B

Fierce Pharma

After proving the merits of its drug delivery platform last year with the approval of Teva’s long-acting schizophrenia drug Uzedy, France’s Medincell has hooked another big-name partner. | Medincell and AbbVie inked a development and licensing pact to create up to six long-acting injectables, Medincell said Wednesday. Under the deal, Medincell is line to receive an upfront payment of $35 million plus much more in potential development and commercial milestones.

277
277
article thumbnail

Telehealth firm Cerebral faces $7m FTC fine over privacy

pharmaphorum

The FTC is seeking a $7 million fine on telehealth company Cerebral for violating patients' data privacy and making cancellation difficult.

Patients 119

More Trending

article thumbnail

Sage drops dalzanemdor for Parkinson’s after trial flop

pharmaphorum

Sage Therapeutics has suffered another disappointment after deciding that it will have to drop the Parkinson’s programme for key pipeline drug dalzanemdor after it showed no benefit in a phase 2 trial. The oral positive allosteric modulator (PAM) of the NMDA receptor is being investigated to see if it can counteract mild cognitive impairment in neurodegenerative disorders, and the PRECEDENT trial in Parkinson’s is the first major readout from the drug programme.

115
115
article thumbnail

Star Ratings and Member Experience: Two Sides of the Same Coin

MedCity News

The challenge? Maintaining high Star Ratings or improving upon existing ratings gets increasingly difficult over time. The post Star Ratings and Member Experience: Two Sides of the Same Coin appeared first on MedCity News.

article thumbnail

Brexit is ‘driving NHS medicines shortages,’ says report

pharmaphorum

Drug shortages fuelled by Brexit are now the 'new normal' in the UK and worsened in 2023, says Nuffield Trust report.

Medicine 111
article thumbnail

Want to Connect with Innovative Healthcare Startups and Investors? Register for MedCity INVEST Today!

MedCity News

In addition to panel discussions around some of the hottest topics in healthcare transformation, there is also a startup pitch contest, a presentation on government funding for startups and networking opportunities. The post Want to Connect with Innovative Healthcare Startups and Investors? Register for MedCity INVEST Today! appeared first on MedCity News.

article thumbnail

From Diagnosis to Delivery: How AI is Revolutionizing the Patient Experience

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

article thumbnail

GSK reveals data on novel gonorrhoea drug gepotidacin

pharmaphorum

GSK reveals data from EAGLE-1 trial of novel antibiotic gepotidacin for gonorrhoea, amid growing resistance to existing antibiotics.

110
110
article thumbnail

LogiPharma Europe 2024: Collaboration on Behalf of Sustainability

Pharmaceutical Commerce

A panel uncovers the value in meeting carbon-neutral goals by 2030.

105
105
article thumbnail

MaaT microbiota drug shows survival advantage in GvHD

pharmaphorum

MaaT Pharma's microbiota therapy MaaT013 shows survival benefit in acute GvHD in an early access programme, boding well for an ongoing phase 3 trial.

Pharma 105
article thumbnail

Pharma Pulse 4/17/24: At-Home Patients and AI, Psychedelics Present Unique Ethical Challenges & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Ethics 105
article thumbnail

How to Prove Marketing Value: Demonstrate Content ROI and Contribution to Sales

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

article thumbnail

FDA Announces Recall of Heart Pumps Linked to Deaths and Injuries

MedCity News

The recall comes years after surgeons say they first noticed problems with the HeartMate II and HeartMate 3, manufactured by Thoratec Corp., a subsidiary of Abbott Laboratories. The devices are not currently being removed from the market. The post FDA Announces Recall of Heart Pumps Linked to Deaths and Injuries appeared first on MedCity News.

FDA 104
article thumbnail

Study reveals how specific nasal cells protect against COVID-19 in paediatric patients

PharmaTimes

The findings suggest why children tend to experience milder symptoms compared to older adults

article thumbnail

Technology advancement driving growth of rapid sterility testing market

European Pharmaceutical Review

A report by Market Research Future has predicted that the rapid sterility testing market will increase in value from $2.3 billion in 2023 to $4.3 billion by 2032. It is expected hold a compound annual growth rate (CAGR) of 8.20 percent between 2023 and 2032. Factors supporting expansion of the rapid sterility testing market Concerns around the safety of biological medicinal products is rising and will contribute to expansion of the sterility testing sector in the subsequent years, according to t

article thumbnail

Lexeo wins fast track designation for Friedreich’s ataxia gene therapy

Pharmaceutical Technology

LX2006 consists of adeno-associated virus (AAV) vector carrying the frataxin gene, responsible for causing Friedreich’s ataxia.

98
article thumbnail

Optimizing Clinical Supply Strategy: Navigating Challenges & Finding Your Ideal Model

article thumbnail

Encouraging data for Roche multiple sclerosis injection

European Pharmaceutical Review

Roche’s twice-yearly, 10-minute subcutaneous injection of OCREVUS ® (ocrelizumab) has shown significant promise for patients with either with relapsing or primary progressive multiple sclerosis (RMS or PPMS). One-year data from the Phase III OCARINA II trial demonstrated a near-complete suppression of relapse activity (97.2 percent had no relapse) in patients through 48 weeks of the treatment.

article thumbnail

ELRIG UK and SRG collaborate to advance life sciences professionals in drug discovery

PharmaTimes

Both companies will facilitate career progression while advancing the life sciences industry

92
article thumbnail

LogiPharma Europe 2024: Infusing Pulse into Your Supply Chain Operation

Pharmaceutical Commerce

Masterclass session addresses looking beyond a dashboard by added capabilities with added value.

90
article thumbnail

FDA Grants Breakthrough Device Designation to Assay Supporting Earlier Diagnosis of Alzheimer Disease

Pharmacy Times

If approved, the test could provide more timely and accurate diagnosis, hopefully mitigating the impact of Alzheimer disease (AD) on individuals and the community.

FDA 70
article thumbnail

Increase Revenue With Better, Faster Sales Onboarding

Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.

article thumbnail

Susan Schniepp of Regulatory Compliance Associates Explores the Impact of QMS on Quality Maturity (INTERPHEX 2024)

PharmaTech

Susan Schniepp, distinguished fellow, Regulatory Compliance Associates, and co-chair of board of directors, Parenteral Drug Association, demonstrates QMS impact on quality maturity at INTERPHEX.

69
article thumbnail

Trials set up filing for Lilly’s tirzepatide in sleep apnoea

pharmaphorum

Eli Lilly’s diabetes and obesity therapy tirzepatide could find a use as a treatment for obstructive sleep apnoea (OSA) after hitting the mark in a pair of phase 3 trials.

64
article thumbnail

Disinfection of Manufacturing Environments: Balancing Efficacy and Cost of Cleaning with Safety and Environmental Impact (INTERPHEX 2024)

PharmaTech

Wenyu Zhang, PhD, addressed new trends in the aseptic industry and the chief concerns companies should keep in mind while weighing their options, at INTERPHEX 2024.

Safety 69
article thumbnail

3 big patent expirations in 2024 and how companies are pivoting

PharmaVoice

As the cliffs approach, pharma companies are tackling the sales hit with diverging strategies.

Sales 59
article thumbnail

European Clinical Supply Planning: Balancing Cost, Flexibility and Time

article thumbnail

Annex 1 Alignment: Addressing Contamination Control and Assessing Risk

PharmaTech

At INTERPHEX 2024, Pharmaceutical Technology sat down with Christa Myers of CRB Group and Nadiyra Walker Speight of Fujifilm Diosynth Biotechnologies to discuss implementation of Annex 1.

article thumbnail

FDA Approves Ustekinumab Biosimilar to Stelara for Treatment of Plaque Psoriasis

Pharmacy Times

Ustekinumab (Stelara; Janssen Immunology) is a human monoclonal antibody that treats immune-mediated diseases such as psoriasis and psoriatic arthritis.

FDA 57
article thumbnail

Keynote Session Highlights Importance of Process Validation and Data Integrity (INTERPHEX 2024)

PharmaTech

Former FDA drug investigator, Daniel Roberts, discusses the importance of updating process validation and maintaining proper data integrity at a keynote session during INTERPHEX.

FDA 64
article thumbnail

Analysis Forecasts Up to 16.5% of Population Will Have Chronic Kidney Disease by 2032

Pharmacy Times

IMPACT CKD, a modeling analysis created by AstraZeneca, includes data about chronic kidney disease across 8 countries, including the United States.

55
article thumbnail

Using Generative AI in Sales: Pros, Cons, and Considerations According to Sellers

Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A